GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Inventories, Finished Goods

Antengene (HKSE:06996) Inventories, Finished Goods : HK$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Antengene Inventories, Finished Goods?

Antengene's quarterly finished goods increased from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$7.18 Mil) but then declined from Dec. 2023 (HK$7.18 Mil) to Jun. 2024 (HK$0.00 Mil).

Antengene's annual finished goods increased from Dec. 2021 (HK$0.61 Mil) to Dec. 2022 (HK$5.94 Mil) and increased from Dec. 2022 (HK$5.94 Mil) to Dec. 2023 (HK$7.18 Mil).

Antengene Inventories, Finished Goods Historical Data

The historical data trend for Antengene's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Inventories, Finished Goods Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial - - 0.61 5.94 7.18

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.94 - 7.18 -

Antengene Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Antengene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Inventories, Finished Goods
Comparable Companies
HKSE:03681 HKSE:02197 HKSE:02142 HKSE:09939 HKSE:02126 HKSE:02185 HKSE:01875 HKSE:06998 HKSE:01228 HKSE:06628 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Website
https://www.antengene.com
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
Executives
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Mei Jay 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines